Phase 2 N=29 Pharmacokinetic Study of Oral Testosterone (T) Ester Formulations in Hypogonadal Men
Hypogonadism
Primary: Serum Testosterone Average Concentration (Cavg) (ng/dL) — 792; 654; 541; 765 ng/dL
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=41 RTA 408 Capsules in Patients With Melanoma - REVEAL
Melanoma · Unresectable (Stage III) Melanoma · Metastatic (Stage IV) Melanoma
Primary: Measure of Efficacy of the Phase 2 Dose of RTA 408 in Combination With Nivolumab Using Overall Response Rate (ORR; Complete Plus Partial Responses) According to RECIST…
Phase 2 N=18 CD8+ Memory T-Cells as Consolidative Therapy After Donor Non-myeloablative Hematopoietic Cell Transplant in Treating Patients With Leukemia or Lymphoma
Acute Myeloid Leukemia · B-Cell Non-Hodgkin Lymphoma · Chronic Lymphocytic Leukemia
Primary: Full-dose Donor Chimerism (FDC) — 12 Participants
Phase 2 N=39 Safety and Tolerability of AIN457 in Adults (18-65 Years) With Moderate to Severe Ankylosing Spondylitis
Ankylosing Spondylitis
Primary: Number of Participants Reported Adverse Events (AE's) — 21; 6; 6; 3 Participants
Phase 2 N=151 Safety, Efficacy and Treatment Regimen Study of ST266 in Subjects With Moderate to Severe Periodontitis
Periodontal Disease
Primary: Changes in Pocket Depth (PD) for Those Pockets ≥ 6 mm at Baseline — 6.6; 6.6; 6.7; 4.5 Pocket Depth (mm) — p=0.341
Phase 2 N=17 Discontinuation or Continuation of Immunosuppressive Therapy in Participants With Chronic Graft Versus Host Disease
Chronic Graft Versus Host Disease
Primary: Feasibility of Enrolling Patients — 21 Participants
Phase 2 N=123 A Double Blind, Randomized, Controlled Study to Evaluate CHF 5633 (Synthetic Surfactant) and Poractant Alfa in Neonates With Respiratory Distress Syndrome (RDS) (POC)
Respiratory Distress Syndrome, Newborn
Primary: Oxygen Requirement and Ventilatory Support -- SpO2/FiO2 Ratio — 3.33; 3.31; 3.36; 3.55 SpO2/FiO2 ratio — p=0.930
Phase 2 N=47 Lung-MAP: Talazoparib in Treating Patients With HRRD Positive Recurrent Stage IV Squamous Cell Lung Cancer
ATM Gene Mutation · ATR Gene Mutation · BARD1 Gene Mutation
Primary: Overall Response Rate Assessed by Response Evaluation Criteria in Solid Tumors 1.1 in HRRD-positive (MDVN) Participants — 4 percentage of participants
Phase 2 N=53 Kanglaite Reduce the Toxicity of Radiotherapy of Head and Neck Cancer Phase II Study
Head and Neck Cancer · Radiotherapy
Primary: the Incidence Rate of Severe Radiation Mucositis — 3; 38; 5; 0 Participants
Phase 2 N=14 AGN-151597 (Formerly RST-001) Phase I/II Trial for Advanced Retinitis Pigmentosa
Advanced Retinitis Pigmentosa
Primary: Number of Participants With Any Grade 3 or Greater Adverse Event (AE) Considered Related to AGN-151597 — 0; 0; 0; 0 participants
Phase 2 N=30 A Study of Erwinaze Administered Intravenously in Patients Who Had an Allergy to Frontline Asparaginase Therapy
Acute Lymphoblastic Leukemia · Lymphoblastic Lymphoma
Primary: Two Day Nadir Serum Asparaginase Activity (NSAA) Level — 0.32 (IU/mL)
Phase 2 N=156 Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in BRAF Mutant Metastatic Colorectal Cancer
Colorectal Cancer
Primary: Phase 1b: Number of Participants With Incidence of Dose Limiting Toxicities (DLTs): Cycle 1 — 0; 1; 1; 1 Participants
Phase 2 N=16 Effect of Beetroot Juice on Blood Pressure Regulation in Post Menopausal Women
Postmenopausal Women
Primary: Resting Aortic Blood Pressures — 113.3; 116.9 mmHg
Phase 2 N=34 An Extension Study to Evaluate the Long-Term Safety and Durability of Effect of LUM001 in the Treatment of Cholestatic Liver Disease in Pediatric Subjects With Alagille Syndrome
Alagille Syndrome
Primary: Change From MRX Baseline to Week 48 in Fasting Serum Bile Acid (sBA) — 223.62; 157.35 μmol/L — p=0.1157
Phase 2 N=6 AMO-01 to Treat Adolescents and Adults With Phelan-McDermid Syndrome (PMS) and Co-morbid Epilepsy
Phelan-McDermid Syndrome · Epilepsy
Primary: Number of Adverse Events — 19 events